Greater China Strategy | Alpha Picks: February Conviction Calls Chinese equities recovered in January, with the HSI and MSCI China rising 6.9% and 5.0% mom, respectively. Given the supportive macro policy environment, we maintain a constructive view on the markets despite risk of further volatility in February. Accordingly, we are adding Alibaba, Ganfeng Lithium, and Minth to our BUY list, while adding Meituan to our SELL list. Indonesia Company Results | Bank Negara Indonesia (BBNI IJ/B...
Singapore equities delivered a strong January performance, with the STI rising 5.6% to fresh record highs amid heightened geopolitical tensions that drove flight-to-safety flows. Manufacturing activity remained in mild expansion, led by electronics and AI-related demand. Market/corporate catalysts during the month include REIT earnings, IPO interest in Catalist and continued strength in gold-linked counters.
Greater China Strategy | 2025 Review; 2026 Outlook In 2025, eight names under our coverage have outperformed the HSI, which has risen 27% ytd. Our key calls JBM Healthcare, Crystal and Plover Bay have gone up 43%, 54% and 31% ytd respectively. Looking into 2026, we have two key themes: ADAS and AI plays. The names on our radar are Horizon Robotics, Karrie International and FIT Hon Teng. We also recommend to buy for quality compounders Crystal, Plover Bay, JBM Healthcare and Jacobson Pharma on di...
Top Stories Company Update | Singapore Exchange (SGX SP/HOLD/S$16.70/Target: S$17.30) SGX’s 5MFY26 trading statistics outperformed our expectations on strong cash equity turnover and healthy derivative volumes. Trading activities are expected to sustain at high levels in 2HFY26, but yoy growth is likely to moderate due to a high 2HFY25 base. We like SGX’s upbeat growth outlook, with a three-year core earnings CAGR of 8.9% in FY25-28, but its current share price is close to our updated target pri...
SGX’s 5MFY26 trading statistics outperformed our expectations on strong cash equity turnover and healthy derivative volumes. Trading activities are expected to sustain at high levels in 2HFY26, but yoy growth is likely to moderate due to a high 2HFY25 base. We like SGX’s upbeat growth outlook, with a three-year core earnings CAGR of 8.9% in FY25-28, but its current share price is close to our updated target price of S$17.30 (25.5x FY27 PE, or 2SD above historical mean). Maintain HOLD.
Greater China Initiation Coverage | Metasurface Technologies Holdings (8637 HK/BUY/HK1.48/Target: HK2.90) Metasurface is set to benefit from robust investment in the semi supply chain. As chip fabrication grows in complexity, more time is required to fabricate wafers and more wafer fabrication equipment is needed. Aerospace engineering is set to drive long-term growth as airline capacity continues to face shortages, forcing airlines to rely on their existing fleets and bo...
Attractive yield differentials. With Singapore government bond yields trending lower, the yield differential between fixed income and equities has narrowed in 2025, thus reinforcing the relative appeal of companies offering high, sustainable dividend payouts. Equity yields in the 4-6% range now offer a compelling pickup versus the 10-year Singapore Government Bond yield (1.8579% as at 4 Sep 25), while also providing potential for capital gains. In our view, this widening yield gap should support...
KEY HIGHLIGHTS Sector Banking: 2Q25 round-up: Delivers resilient earnings despite NIM compression. Maintain OVERWEIGHT. Results Lendlease Global Commercial REIT (LREIT SP/BUY/S$0.575/Target: S$0.79): 2HFY25: Sharpening competitive advantage by focusing on Singapore. Riverstone Holdings (RSTON SP/HOLD/S$0.69/Target: S$0.71): 2Q25: Results miss on lower ASPs; cleanroom recovery expected in 2H25. Sembcorp Industries (SCI SP/BUY/S$6.72/Target: S$7.90): 1H25: Curtail the worry – focus on defensive ...
GREATER CHINA Economics Inflation Deflationary pressures persist despite core CPI resilience. INDONESIA Update Darma Henwa (DEWA IJ/BUY/Rp222/Target: Rp372) Sustaining the growth momentum. MALAYSIA Update Uzma (UZMA MK/BUY/RM0.41/Target: RM0.76) Aggressive orderbook growth driven by O&G. However, its five-year recurring income target will miss, due to del...
SGX’s FY25 core net profit of S$609.5m (+15.9% yoy) is in line with our expectations, at 99% of our forecast. SGX saw broad-based growth across all business segments in FY25. FY26 outlook remains upbeat, with the cash equity business to be bolstered by the MAS EQDP, and the derivative business driven by risk management demand amid heightened global uncertainties. Maintain HOLD with a higher target price of S$16.66. Its new dividend policy is a key positive. Accumulate on share price dips.
GREATER CHINA Sector Automobile: Weekly: China’s 60-day payment rule reshapes autos. Maintain MARKET WEIGHT on the sector. Top BUYs: Desay SV and Tuopu. Home Appliance: Expect suspension of government subsidies to be temporary but may lead to postponement of consumer purchases. Results JBM Healthcare (2161 HK/BUY/HK$2.59/Target: HK$3.11): FY25: Record-high dividends; positive FY26 outlook. INDONESIA Update Mitra Adiperkasa (MAPI IJ/HOLD/Rp1,265/Target: Rp1,300): Expect a moderate SSSG of 3% yoy...
SGX reported strong operating statistics which saw SDAV grow in May 25, driven by increased market turnover value for the financial and telco sectors. Total derivative traded volumes also grew, largely driven by higher forex futures but dragged by softer volumes from equity index and commodity futures. Despite the upcoming deployment of the S$5b EMDP fund, we opine that SGX is fairly valued at current price levels. Maintain HOLD but with a higher PE-based target price of S$14.08.
GREATER CHINA Strategy China And Hong Kong Property & Hong Kong Landlord Tariffs curtail US rate cuts, thereby hindering the recovery of Hong Kong property and tourism; Maintain OVERWEIGHT on China property. INDONESIA Strategy Alpha Picks: Outperform In Mar 25 Remove BBNI, BBRI, ASII, JSMR and KLBF; add BBCA, ICBP, ERAA and BUKA. MALAYSIA Update Pekat Group (PEKAT MK/BUY/RM1.08/Target: RM1.45) Good earnings visibility over 2025...
The selloff driven by the US’ unprecedented and perplexing tariff plans has liberated many investors of profits this year. Given the fluidity of market conditions, we highlight a number of domestic-focused stocks such as CENT, CD, DFI, HLA, PANU, PROP, RFMD, SSG and SIE as well as Singapore-focused REITS such as CDLHT, FEHT, FCT, KREIT, LREIT and PREIT. In addition, the MAS’ equity market review should inject much needed liquidity in 2H25. We lower our STI target to 3,720 (previously 4,115).
KEY HIGHLIGHTS Results Lendlease Global Commercial REIT (LREIT SP/BUY/S$0.53/Target: S$0.72) 1HFY25: Resilient contributions from Singapore; upside from office block at Jem. Singapore Exchange (SGX SP/HOLD/S$12.71/Target: S$12.58) 1HFY25: Record-high earnings driven by all business segments. Update Wilmar International (WIL SP/HOLD/S$3.26/Target: S$3.18) 4Q24 results preview: Better performance qoq, but lower yoy on lacklustre China operations and delayed sugar harvest. TRADERS' CORNER Seatr...
GREATER CHINA Strategy Small-Mid Cap Monthly: Countdown to Plover Bay’s 2024 results: Eyeing final dividend and 2025 outlook. Sector Automobile: Weekly: OEMs post upbeat January sales. Maintain MARKET WEIGHT. Top BUYs: Geely, CATL, Fuyao and Desay. Update Aier Eye Hospital Group (300015 CH/HOLD/Rmb12.71/Target: Rmb13.80): Expecting slower growth amid weaker demand, yet outperforming peers. Downgrade to HOLD. INDONESIA Results XL Axiata (EXCL IJ/BUY/Rp2,290/Target: Rp3,300): 4Q24: NPAT jumps 93%...
For 1HFY25, SGX reported record-high revenue (+15.2% yoy) and adjusted PATMI (+27.3% yoy), driven by broad-based growth across all business segments. The cash equities and equity derivatives segments were clear outperformers on the back of higher SDAV and total traded volumes while the FICC segment continued its upward momentum. However, we opine that SGX is fairly valued at current price levels. Maintain HOLD but with a higher target price of S$12.58.
GREATER CHINA Economics Trade Export Growth Rebounded; Rush Order Ahead Of Tariffs? Sector Education Key growth themes in 2025 upon policy clarity and AI integration progress. Property Sales pull back mom before Chinese New Year; updates of 2024 op...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.